title: Pretreatment clinical variables associated with the response to intravitreal bevacizumab (Avastin) injection in patients with persistent diabetic macular edema.
abstract: BACKGROUND
  The purpose of the study is to determine whether the pre-treatment clinical systemic variables and optical coherence tomography (OCT) findings are associated with the subsequent response to the intravitreal bevacizumab (IVB) in eyes with persistent diabetic macular edema (DME).
  
  
  METHODS
  Prospective, interventional non-comparative case series study.
  
  
  METHODS
  38 Patients (45 eyes) with refractory diabetic macular edema; 16 females, 22 males with a mean aged 57.5 year. All patients had persistent DME not responded to other forms of treatments. Complete eye examination; best corrected visual acuity (BCVA) (represented as LOGMAR for adequate statistical analysis), slit-lamp exam, intraocular pressure measurement, stereoscopic biomicroscopy of the macula, and morphologic patterns of diabetic macular edema demonstrated by OCT. All patients had intravitreal injection of 0.05 mL = 1.25 mg bevacizumab (Avastin; Genentech, Inc., San Francisco, CA), and were followed up for 3 months. The pre and post-injection follow-up data were analyzed by Student-t test and Mann-Whitney test for two main outcome measures; visual acuity (LOGMAR) and central foveal thickness (CFT) changes over a period of three months, and the data included demographic factors, type, duration and the control of diabetes mellitus (HbA1C%), grade of diabetic retinopathy, renal function (serum creatinine level), serum cholesterol, blood pressure control and previous treatment by focal laser and/or intravitreal triamcinolone injection.
  
  
  RESULTS
  The LOGMAR and central foveal thickness (CRT) improved in 30/45 eyes (67%) and 32/45 eyes (72%), respectively during a mean follow-up time of three months. The mean LOGMAR visual acuities were 0.64 (SD ± 0.34), 0.61 (SD ± 0.31) and 0.60 (SD ± 0.32) at pre-injection, at 1 month post-injection and at 3 months post-injection, respectively; but this mean increase in vision was statistically not significant (P value = 0.099). The mean foveal thicknesses were 444.95 μm (SD ± 127.36), 394.95 μm (SD ± 138.03) and 378.32 μm (SD ± 112.01) at pre-injection, 1 month post-injection and 3 months post-injection, respectively, this decrease in the foveal thickness was statistically significant (P value <0.001). The pre and post-injections values of the variables for diabetic duration, diabetic control (HbA1c) and OCT pattern of macular edema showed significant statistical correlations (P < 0.05) with LOGMAR only, however the values of the variables for serum creatinine and cholesterol show statistical correlation (P < 0.05) with both LOGMAR and CFT.
  
  
  CONCLUSIONS
  Chronicity and inadequate control of diabetes mellitus, nephropathy, hyperlipidemia and presence of vitreomacular attachment (VMA) are factors associated with poor vision progress after intravitreal bevacizumab injection.
authors: HMC, Ophthalmology Department, P.O. Box 3050, Doha, Qatar.
authors: Fareed A
authors: FA
authors: Warid Al-Laftah
authors: Maha
authors: M
authors: Elshafie
authors: Mustafa
authors: M
authors: Alhashimi
authors: Aant
authors: A
authors: Pai
authors: Mohammad
authors: M
authors: Farouq
keywords: Bevacizumab (Avastin); CSME; Systemic factors and OCT
references: Arch Ophthalmol. 1985 Dec;103(12):1796-806
references: 2866759
references: Am J Ophthalmol. 2004 Jul;138(1):158-60
references: 15234306
references: Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):336-9
references: 16156153
references: Circulation. 2008 Jun 24;117(25):e510-26
references: 18574054
references: Diabetes Care. 1992 Aug;15(8):1002-8
references: 1505300
references: Am J Ophthalmol. 2007 Jul;144(1):124-6
references: 17601433
references: Retina. 2006 Mar;26(3):279-84
references: 16508427
references: Lancet. 1993 May 22;341(8856):1306-9
references: 8098449
references: Arch Ophthalmol. 2001 Feb;119(2):251-9
references: 11176988
references: Semin Ophthalmol. 2004 Mar-Jun;19(1-2):13-20
references: 15658007
references: Ophthalmology. 1991 Aug;98(8):1261-5
references: 1923364
references: Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3655-64
references: 11006264
references: Am J Ophthalmol. 2006 Sep;142(3):405-12
references: 16935584
references: N Engl J Med. 1993 Sep 30;329(14):977-86
references: 8366922
references: Diabetes Care. 1996 Nov;19(11):1291-3
references: 8908399
references: Ophthalmology. 2003 Apr;110(4):681-6
references: 12689886
references: Diabetes Res Clin Pract. 2002 May;56(2):125-31
references: 11891020
references: Diabetologia. 2001 Feb;44(2):156-63
references: 11270671
references: Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5
references: 16156152
references: Arch Ophthalmol. 1996 Sep;114(9):1079-84
references: 8790092